-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Daratumumab in Systemic Lupus Erythematosus
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Daratumumab in Systemic Lupus Erythematosus report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Daratumumab in Systemic Lupus Erythematosus Drug Details: Daratumumab ((HuMax-CD38, JNJ-54767414,...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Brexucabtagene Autoleucel in Primary Mediastinal B-Cell Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Brexucabtagene Autoleucel in Primary Mediastinal B-Cell Lymphoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Brexucabtagene Autoleucel in Primary Mediastinal B-Cell Lymphoma Drug...
-
Innovation Ranking
Innovation Ranking – Evelo Biosciences Inc
Evelo Biosciences Inc (Evelo Biosciences) is a biotechnology company. It develops orally delivered product candidates for the treatment of inflammatory diseases and cancer. The company is investigating pipeline product EDP1815 and EDP1867, targeting SARS-CoV-2 virus, psoriasis, atopic dermatitis, and inflammatory diseases; and EDP1908, an anti-PD-1 therapy for multiple cancers. Its proprietary Sintax, an integrated platform develops oral biologics which harness the cells in the small intestine. Evelo Biosciences is also evaluating novel therapies to treat chronic diseases and cancer. The...
-
Product Insights
NewPlaque Psoriasis (Psoriasis Vulgaris) – Drugs In Development, 2024
Empower your strategies with our Plaque Psoriasis (Psoriasis Vulgaris) – Drugs In Development, 2024 report and make more profitable business decisions. Plaque psoriasis, also known as psoriasis vulgaris, is the most common form of psoriasis, a chronic skin condition characterized by the rapid buildup of skin cells. It results from an overactive immune system, causing skin cells to accumulate on the surface, forming thick, scaly, and often itchy patches or plaques. These patches can vary in size and typically have a...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Ribociclib Succinate in Oligodendroglioma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Ribociclib Succinate in Oligodendroglioma Drug Details: Ribociclib succinate (Kisqali, Kryxana) is an antineoplastic agent. It...
-
Product Insights
NewNet Present Value Model: Ocugen Inc’s OCU-400
Empower your strategies with our Net Present Value Model: Ocugen Inc's OCU-400 report and make more profitable business decisions.Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewNet Present Value Model: Evelo Biosciences Inc’s EDP-1815
Empower your strategies with our Net Present Value Model: Evelo Biosciences Inc's EDP-1815 report and make more profitable business decisions.Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – EDP-1815 in Plaque Psoriasis (Psoriasis Vulgaris)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - EDP-1815 in Plaque Psoriasis (Psoriasis Vulgaris) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. EDP-1815 in Plaque Psoriasis (Psoriasis Vulgaris) Drug Details: EDP-1815...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Lipocurc in Glioblastoma Multiforme (GBM)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Lipocurc in Glioblastoma Multiforme (GBM) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Lipocurc in Glioblastoma Multiforme (GBM)Drug Details:Liposomal curcumin is under development for the...